$QTRX

Quanterix Corp (QTRX): Submission of Matters to a Vote of Security Holders

Quanterix Corp (QTRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. qtrx-20260609 Quanterix Corp false 0001503274 0001503274 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 8-K ______________________________________ CURRENT REPORT Pursuant to Section 13 or 1

Original reporting
Published Jun 10, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 10, 2026, 8:17 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$QTRX
Neutral
low confidence
Mentioned
$QTRX
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QTRXNeutralLow
01

Why it matters

Key items: Proposal 1 (two independent director elections) and Proposal 2 (advisory say-on-pay) were approved; Proposal 3 (KPMG ratification) was approved; Proposal 4 (amend and restate the 2017 equity incentive plan, extending through June 9, 2031) was not approved.

02

Market read

The only new tradable element is the disclosed outcome of the equity plan amendment (Proposal 4 rejected), alongside governance vote results.

03

What to watch

Traders may overreact to the rejected proposal; the filing lacks details on whether the company will re-submit a revised plan or how it affects actual equity grants.

Relevance 6/10Novelty 4/10Timing: Filed after the June 9, 2026 annual meeting vote; available after-hours/next session.

Background

This SEC 8-K Item 5.07 reports the results of proposals voted on at Quanterix’s June 9, 2026 annual meeting, as described in its April 24, 2026 proxy materials.

Company-level read

Ticker impact

$QTRXNeutralLow confidence
Context

Quanterix reported 2026 annual meeting vote results, including director elections, say-on-pay, KPMG ratification, and rejection of an equity plan amendment.

Expected impact

Likely limited near-term impact; any reaction would be modest and driven by investor interpretation of the rejected equity plan amendment.

Evidence & confidence

The 8-K discloses voting tallies (including Proposal 4 failing) but provides no new financial guidance, contract, or regulatory decision.

Market effects

Minimal; this is company-specific governance and equity-plan mechanics.

None indicated.

None indicated.

Counterpoint

The rejected equity plan amendment could be a temporary governance setback, but it may also reduce near-term dilution risk versus an approved plan extension.

Key entities

  • Quanterix Corporation

    Nasdaq-listed company whose shareholder vote results were filed on Form 8-K.

  • KPMG LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

  • William P. Donnelly

    Independent director nominee elected for a one-year term expiring in 2027.

  • Ivana Magovčević-Liebisch, Ph.D., J.D.

    Independent director nominee elected for a one-year term expiring in 2027.

Related articles

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.

$QTRXMed

Quanterix Q2 Earnings Call Highlights

Quanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.

$QTRXHigh

Quanterix Corp (QTRX): Results of Operations and Financial Condition

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2026 Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends

$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.